(140 days)
Not Found
No
The document explicitly states "Mentions AI, DNN, or ML: Not Found" and the description focuses on electrochemical sensing and fluidics.
No
The device is described as an in vitro diagnostic analytical device intended for the quantitative measurement of glucose, used in the diagnosis, monitoring, and treatment of carbohydrate metabolism disorders. It does not directly treat or prevent a disease.
Yes
The "Intended Use / Indications for Use" section explicitly states, "Glucose measurements are used in the diagnosis, monitoring, and treatment of carbohydrate metabolism disorders". This directly indicates a diagnostic purpose. The "Device Description" also mentions it is an "in vitro diagnostic analytical device."
No
The device description explicitly states that the i-STAT Alinity System is comprised of hardware components including an instrument, battery, base station, electronic simulator, control material, and printer, in addition to the test cartridges. This indicates it is a hardware-based system with integrated software, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section clearly states: "For in vitro diagnostic use."
- Device Description: The "Device Description" section also states: "The i-STAT System is a handheld, in vitro diagnostic analytical device..."
- Function: The device is designed to measure glucose in whole blood samples, which is a test performed in vitro (outside the body) to aid in the diagnosis, monitoring, and treatment of medical conditions.
N/A
Intended Use / Indications for Use
The i-STAT Alinity System with i-STAT Glucose test is intended for use or clinical laboratory settings. The i-STAT Alinity System with Glucose test is intended for the quantitative measurement of glucose in arterial and venous whole blood.
Glucose measurements are used in the diagnosis, monitoring, and treatment of carbohydrate metabolism disorders including, but not limited to, diabetes mellitus, idiopathic hypoglycemia, and pancreatic islet cell carcinoma. The i-STAT Glucose test with the i-STAT Alinity System has not been evaluated in neonates.
For in vitro diagnostic use.
Product codes (comma separated list FDA assigned to the subject device)
CGA
Device Description
The i-STAT System is a handheld, in vitro diagnostic analytical device designed to run only i-STAT test cartridges. The system is designed for use by trained medical professionals at the patient point of care or in the clinical laboratory and is for prescription use only.
The i-STAT Alinity System is comprised of the instrument, rechargeable battery, base station, electronic simulator, control material, printer and i-STAT test cartridges. The i-STAT Alinity Instrument features a barcode scanner, user interface with touch screen display and wireless capability. The instrument reports quantitative results within approximately 2 minutes.
The i-STAT test cartridge contains test reagents which are located on the sensors. The instrument interacts with the cartridge to move fluid across the sensors and generate a quantitative result. Cartridges require two to three drops of whole blood which are typically applied to the cartridge using a syringe.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
The i-STAT Glucose test with the i-STAT Alinity System has not been evaluated in neonates.
Intended User / Care Setting
trained medical professionals at the patient point of care or in the clinical laboratory.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Analytical Performance
- Precision (aqueous materials): Evaluated over 20 days using 5 levels of aqueous materials. Study conducted with 10 instruments and one test cartridge lot. Total precision CV ranged from 0.26% to 1.56%.
- Precision (whole blood): Evaluated using venous whole blood samples at six glucose levels across 3 point of care sites. Each sample tested 3 times on each of 7 i-STAT Alinity Instruments. Total precision %CV ranged from 0.21% to 1.59%.
- Linearity: Evaluated by preparing a series of glucose concentration levels in whole blood. Demonstrated linearity over the reportable range (20-700 mg/dL).
- Recovery: Evaluated by creating series of glucose concentration levels in whole blood. % recovery ranged from 94.6% to 100.3% across the glucose reportable range (20-700 mg/dL).
- Limit of Quantitation (LoQ): Determined to be 5.558 mg/dL using altered whole blood samples (
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
April 10, 2017
ABBOTT POINT OF CARE INC. MARIA L. FIGUEROA SR. SPECIALIST REGULATORY AFFAIRS 400 COLLEGE ROAD EAST PRINCETON NJ 08540
Re: K163271
Trade/Device Name: i-STAT Alinity System with i-STAT Glucose test Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: II Product Code: CGA Dated: March 13, 2017 Received: March 14, 2017
Dear Ms. Maria Figueroa:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Kellie B. Kelm -S
for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K163271
Device Name i-STAT Alinity System with i-STAT Glucose test
Indications for Use (Describe)
The i-STAT Alinity System with i-STAT Glucose test is intended for use or clinical laboratory settings. The i-STAT Alinity System with Glucose test is intended for the quantitative measurement of glucose in arterial and venous whole blood.
Glucose measurements are used in the diagnosis, monitoring, and treatment of carbohydrate metabolism disorders including, but not limited to, diabetes mellitus, idiopathic hypoglycemia, and pancreatic islet cell carcinoma. The i-STAT Glucose test with the i-STAT Alinity System has not been evaluated in neonates.
For in vitro diagnostic use.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
The information in this 510(k) summary is being submitted in accordance with the requirements of 21CFR 807.92.
| 1. | Submitter Information
Owner | Abbott Point of Care Inc.
400 College Road East
Princeton, NJ 08540 | | |
|----|--------------------------------|----------------------------------------------------------------------------------------------------------------------|--|--|
| | Contact | Primary: Maria L Figueroa
Sr. Specialist Regulatory Affairs
maria.l.figueroa@abbott.com
Phone: 609-454-9271 | | |
| | | Secondary: Susan Tibedo
Director Regulatory Affairs
susan.tibedo@abbott.com
Phone: 609-454-9360 | | |
| | Date Prepared | April 6, 2017 | | |
2. Device Information
Proprietary Name i-STAT Alinity System with the i-STAT Glucose test 510(k) Number: K163271
| Product
code | Device Classification
name | Regulation
Number | Class | Panel |
|-----------------|-------------------------------|----------------------|-------|--------------------|
| CGA | Glucose Test System | 862.1345 | II | Clinical Chemistry |
3. Predicate Device
| Proprietary Name | i-STAT 1 Wireless Analyzer |
|---|---|
| ------------------ | ---------------------------- |
510(k) Number K103195
| Product
code | Device Classification
name | Regulation
Number | Class | Panel |
|-----------------|-------------------------------|----------------------|-------|--------------------|
| CGA | Glucose Test System | 862.1345 | II | Clinical Chemistry |
4
4. Device Description
The i-STAT System is a handheld, in vitro diagnostic analytical device designed to run only i-STAT test cartridges. The system is designed for use by trained medical professionals at the patient point of care or in the clinical laboratory and is for prescription use only.
The i-STAT Alinity System is comprised of the instrument, rechargeable battery, base station, electronic simulator, control material, printer and i-STAT test cartridges. The i-STAT Alinity Instrument features a barcode scanner, user interface with touch screen display and wireless capability. The instrument reports quantitative results within approximately 2 minutes.
The i-STAT test cartridge contains test reagents which are located on the sensors. The instrument interacts with the cartridge to move fluid across the sensors and generate a quantitative result. Cartridges require two to three drops of whole blood which are typically applied to the cartridge using a syringe.
5. Intended Use Statement
The i-STAT Alinity System with i-STAT Glucose test is intended for use in point of care or clinical laboratory settings. The i-STAT Alinity System with Glucose test is intended for the quantitative measurement of glucose in arterial and venous whole blood.
Glucose measurements are used in the diagnosis, monitoring, and treatment of carbohydrate metabolism disorders including, but not limited to, diabetes mellitus, idiopathic hypoglycemia, and pancreatic islet cell carcinoma.
The i-STAT Glucose test with the i-STAT Alinity System has not been evaluated in neonates.
For in vitro diagnostic use.
5
| Similarities and Differences: System (Test and Instrument) | ||
|---|---|---|
| Feature or | ||
| Characteristic | Predicate Device (K103195) | |
| i-STAT Glucose test with the | ||
| i-STAT 1 Wireless Analyzer | Candidate Device | |
| i-STAT Glucose test with the | ||
| i-STAT Alinity instrument | ||
| Intended Use | The i-STAT 1 Wireless Analyzer | |
| is used by trained medical | ||
| professionals for running a | ||
| variety of clinical chemistry tests | ||
| and test panels contained in i- | ||
| STAT test cartridges. |
The test for glucose, as part of
the i-STAT System, is intended
for use in the in vitro
quantification of glucose in
arterial, venous, or capillary
whole blood. | The i-STAT Alinity System with
i-STAT Glucose test is intended
for use in point of care or clinical
laboratory settings. The i-STAT
Alinity System with Glucose test
is intended for the quantitative
measurement of glucose in
arterial and venous whole blood. |
| | Glucose measurements are used
in the diagnosis, monitoring, and
treatment of carbohydrate
metabolism disorders including,
but not limited to, diabetes
mellitus, neonatal hypoglycemia,
idiopathic hypoglycemia, and
pancreatic islet cell carcinoma. | Glucose measurements are used
in the diagnosis, monitoring, and
treatment of carbohydrate
metabolism disorders including,
but not limited to, diabetes
mellitus, idiopathic
hypoglycemia, and pancreatic
islet cell carcinoma.
The i-STAT Glucose test with
the i-STAT Alinity System has
not been evaluated in neonates.
For in vitro diagnostic use. |
| | Principle of
Measurement | Glucose is measured
amperometrically. Oxidation of
glucose, catalyzed by the enzyme
glucose oxidase, produces
hydrogen peroxide (H2O2). |
| Calibration | 1-point on-board (contained within
the cartridge) | Same |
| Test
Traceability | NIST SRM965 | Same |
| Test
Reportable
Range | 20 - 700 mg/dL | Same |
| Sample Type | Fresh capillary, arterial or venous
whole blood. | Fresh arterial or venous whole
blood. |
| Sample
Volume | 65 - 95 µL | Same |
| Similarities and Differences: System (Test and Instrument) | | |
| Feature or
Characteristic | Predicate Device (K103195)
i-STAT Glucose test with the
i-STAT 1 Wireless Analyzer | Candidate Device
i-STAT Glucose test with the
i-STAT Alinity instrument |
| Time to test | ~2 minutes | Same |
| Test Format | Cartridge | Same |
| Test
preparation | Ready to use | Same |
| Test Storage
and Stability | Storage: 2°C to 8°C (35-46°F) | Same |
| Quality Checks | A series of quality checks are
automatically run each test cycle
prior to the system generating a
result. Quality checks verify the
analyzer motor, electrical,
pressure and temperature systems
and cartridge elements. | Same |
| Wireless
connectivity
capability | Yes | Same |
| Power | Two 9-volt lithium batteries, or
rechargeable battery. | Lithium-Ion rechargeable battery |
| Barcode
scanning
capability | Yes | Same |
| Data storage
capability | Yes | Same |
| User Interface | 19 keys for data entry | LCD touch screen |
| User Interface
Screen | A grey scale LCD (3.5 in.) | A color LCD screen (5 in.) |
6. Summary Comparison of Technological Characteristics
6
7
7. Performance Characteristics
Analytical Performance
a. Precision
Precision 20 days (aqueous materials)
The precision of the i-STAT Glucose Test on the i-STAT Alinity Instrument was evaluated using 5 levels of aqueous materials. This 20-day multi-day precision testing was based on CLSI document EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline-Third Edition. The study was conducted using 10 instruments and one test cartridge lot over 20 days at one site. Total precision ('within-laboratory', Sr), within-run, (Sr), between-run, (Sr) and between-day, (Saa) were estimated for each level. The results of the 20-day precision study are shown in Table 1.
Table 1: 20-day Precision Study Results
| Calibration
Verification
Level | N | Mean
(mg/dL) | ST
(mg/dL) | CVT
(%) | Sr
(mg/dL) | CVr
(%) | Srr
(mg/dL) | CVrr
(%) | Sdd
(mg/dL) | CVdd
(%) |
|--------------------------------------|----|-----------------|---------------|------------|---------------|------------|----------------|-------------|----------------|-------------|
| CV L1 | 80 | 26.9 | 0.42 | 1.56 | 0.22 | 0.82 | 0.34 | 1.26 | 0.12 | 0.45 |
| CV L2 | 80 | 41.0 | 0.34 | 0.83 | 0.20 | 0.49 | 0.18 | 0.44 | 0.21 | 0.51 |
| CV L3 | 80 | 125.0 | 0.32 | 0.26 | 0.21 | 0.17 | 0.23 | 0.18 | 0.09 | 0.07 |
| CV L4 | 80 | 286.7 | 0.77 | 0.27 | 0.53 | 0.18 | 0.52 | 0.18 | 0.22 | 0.08 |
| CV L5 | 80 | 600.6 | 3.47 | 0.58 | 2.42 | 0.40 | 2.26 | 0.38 | 1.06 | 0.18 |
Precision (whole blood)
The whole blood precision of the i-STAT Glucose Test on the i-STAT Alinity Instrument was evaluated using venous whole blood (native or altered) samples targeted to six different glucose levels within the i-STAT Glucose test reportable range.
One test cartridge lot was used across 3 point of care sites. At each site, each sample was tested 3 times on each of 7 i-STAT Alinity Instruments (total of 21 test results per sample). The results of the whole blood precision are shown in Table 2.
8
| Concentration
Level
(mg/dL) | Site | N | Mean
(mg/dL) | Within-
Instrument | | Total | | | |
|-----------------------------------|------|----|-----------------|-----------------------|------|-------|---------------|------|---------------|
| | | | | SD | %CV | SD | SD 95%
CI | %CV | %CV 95%
CI |
| 30-50 | 1 | 21 | 37.1 | 0.36 | 0.97 | 0.36 | (0.27, 0.52) | 0.97 | (0.74, 1.40) |
| | 2 | 21 | 35.3 | 0.56 | 1.59 | 0.56 | (0.43, 0.81) | 1.59 | (1.21, 2.30) |
| | 4 | 21 | 43.6 | 0.51 | 1.16 | 0.51 | (0.39, 0.73) | 1.16 | (0.89, 1.68) |
| 51-110 | 1 | 21 | 104.0 | 0.22 | 0.21 | 0.22 | (0.17, 0.32) | 0.21 | (0.16, 0.30) |
| | 2 | 21 | 84.5 | 0.51 | 0.61 | 0.51 | (0.39, 0.74) | 0.61 | (0.46, 0.88) |
| | 4 | 21 | 92.7 | 0.46 | 0.50 | 0.46 | (0.35, 0.67) | 0.50 | (0.38, 0.72) |
| 111-150 | 1 | 21 | 134.6 | 0.49 | 0.36 | 0.51 | (0.39, 0.74) | 0.38 | (0.29, 0.55) |
| | 2 | 21 | 120.3 | 0.64 | 0.54 | 0.64 | (0.49, 0.93) | 0.54 | (0.41, 0.77) |
| | 4 | 21 | 115.3 | 0.48 | 0.42 | 0.48 | (0.37, 0.70) | 0.42 | (0.32, 0.61) |
| 151-250 | 1 | 21 | 182.9 | 0.70 | 0.38 | 0.70 | (0.54, 1.01) | 0.38 | (0.29, 0.55) |
| | 2 | 21 | 194.0 | 0.63 | 0.33 | 0.63 | (0.48, 0.91) | 0.33 | (0.25, 0.47) |
| | 4 | 21 | 217.2 | 0.49 | 0.22 | 0.54 | (0.41, 0.81) | 0.25 | (0.19, 0.37) |
| 251-400 | 1 | 21 | 347.3 | 1.71 | 0.49 | 1.71 | (1.31, 2.47) | 0.49 | (0.38, 0.71) |
| | 2 | 21 | 352.0 | 1.43 | 0.41 | 1.43 | (1.09, 2.07) | 0.41 | (0.31, 0.59) |
| | 4 | 21 | 348.7 | 2.53 | 0.73 | 2.53 | (1.94, 3.66) | 0.73 | (0.56, 1.05) |
| 401-700 | 1 | 21 | 548.9 | 7.46 | 1.36 | 7.46 | (5.70, 10.78) | 1.36 | (1.04, 1.96) |
| | 2 | 21 | 575.8 | 2.60 | 0.45 | 2.81 | (2.13, 4.13) | 0.49 | (0.37, 0.72) |
| | 4 | 21 | 526.5 | 3.56 | 0.68 | 3.56 | (2.72, 5.14) | 0.68 | (0.52, 0.98) |
Table 2: Whole Blood Precision Results
b. Linearity
The study was designed based on CLSI EP06-A: Evaluation of the linearity of quantitative measurement procedures. The linearity of the i-STAT Glucose test was evaluated on the i-STAT Alinity Instruments by preparing a series of glucose concentration levels in whole blood that spanned the reportable range of the test. The best fitting regression model was a second order model, and the absolute value of non-linearity ranged from 0.00 to 23.8 mg/dL. The i-STAT Glucose test used with the i-STAT Alinity Instruments demonstrated linearity over the reportable range (20-700 mg/dL).
9
c. Recovery
The recovery of the i-STAT Glucose test was evaluated on the i-STAT Alinity Instrument by creating a series of glucose concentration levels in whole blood, measuring their assigned value on the predicate and determining the recovery bias and % recovery. The % recovery ranged from 94.6% to 100.3% across the glucose reportable range (20-700 mg/dL).
d. Limit of Ouantitation (LoO)
The study was based on the CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition. The LoO of the i-STAT Glucose test was evaluated on the i-STAT Alinity Instruments using whole blood that was altered to low glucose concentrations ( 10% of the mean of glucose test results for the control sample. Compounds that do not interfere with the glucose test are shown in
Table 3; those compounds that do interfere are shown in Error! Reference source not found..
| Substance | Test Concentration | |
|---|---|---|
| (mmol, unless specified) | mg/dL | |
| Acetaminophen | 1.33 | 20.10 |
| Acetaldehyde | 0.045 | 0.20 |
| Substance | Test Concentration | |
| (mmol, unless specified) | mg/dL | |
| Acetoacetate | 2.0 | 21.60 |
| L-Ascorbic Acid | 0.342 | 6.02 |
| Acetyl Cysteine | 10.2 | 166.45 |
| Ammonium Chloride | 2.0 | 10.70 |
| Bromide | 37.5 | 325.69 |
| β-Hydroxybutyric Acid | 6.00 | 62.47 |
| Dopamine | 0.006 | 0.09 |
| Ethanol | 86.8 | 399.89 |
| Fluoride | 0.105 | 0.27 |
| Formaldehyde | 0.133 | 0.40 |
| Glycolic Acid | 10.0 | 76.05 |
| Gentamicin | 0.021 | 3.13 |
| Glucosamine | 0.030 | 0.54 |
| Glutathione, reduced | 3 | 92.20 |
| Guaifenesin | 15 | 297.33 |
| Hemoglobin | 2g/L | 200 |
| Heparin | 3U/mL | n/a |
| Ibuprofen | 2.425 | 50.03 |
| Isoniazid | 0.292 | 4.00 |
| Lactate | 6.6 | 63.37 |
| Mannose | 1.00 | 18.02 |
| Maltose | 13.3 | 455.26 |
| pH | 8.0 | n/a |
| Pyruvate | 0.309 | 2.90 |
| Salicylate | 4.34 | 62.52 |
| Thiocyanate | 6.9 | 44.86 |
| Triglyceride | 37 | 3233.80 |
| Uric Acid | 1.4 | 23.54 |
| Sodium Thiosulfate | 16.7 | 264.04 |
| Bilirubin | 0.342 | 19 |
| Cholesterol | 13 | 503 |
| Creatinine | 0.442 | 5 |
| Fructose | 1 | 18 |
| Galactose | 0.84 | 15 |
| Xylose | 3 | 45 |
Table 3: Non-Interfering Compounds and Test Concentrations
10
11
A hydroxyurea concentration above 0.43 mmol/L may give a falsely elevated i-STAT glucose test result of more than 10%.
f. Anticoagulant Study
The sample type comparison study was performed using the i-STAT Glucose Test on the i-STAT Alinity Instrument and 40 blood samples across the glucose concentration range. The comparator condition for this study was heparinized whole blood and the test condition was non-anticoagulated whole blood. The Deming regression result was a slope of 1.00 and a correlation coefficient of 1.00.
g. Altitude study
The effects of altitude were evaluated for the i-STAT Glucose test on the i-STAT Alinity Instrument at altitude of up to 10.000 feet above sea level. The altitude performance was evaluated using two lots of cartridges, commercially available i-STAT Glucose control materials that represented 3 Glucose levels.
The performance of the i-STAT Glucose test used with the i-STAT Alinity Instrument at altitude up to 10,000 feet was found to be equivalent to the performance of the i-STAT Glucose test at sea level.
h. Oxygen study
The effects of Oxygen were evaluated for the i-STAT Glucose test on the i-STAT Alinity Instrument using whole blood samples. The performance of the i-STAT Glucose test was evaluated at low and high levels of oxygen at four glucose levels
This study demonstrated equivalent glucose results when evaluated at low and high oxygen levels for all glucose concentrations tested.
12
Comparison Study
Method Comparison with Predicate Device i.
The method comparison study compared the clinical results of the i-STAT Glucose Test on the i-STAT Alinity Instrument to the i-STAT Glucose Test performance on the i-STAT 1 Wireless Analyzer (predicate). This study was conducted across 3 point of care sites. The study included 237 subjects using whole blood (venous or arterial) samples covering the measuring range 24 to 673 mg/dL. The Weighted Deming regression for all 3 sites combined had a regression slope of 0.999, intercept of 1.164 and correlation coefficient of 1.000.
8. Conclusion
Analytical and clinical studies have shown the i-STAT Glucose test with the i-STAT Alinity System to be safe and effective for its intended use. The results of these studies demonstrate that performance of the i-STAT Glucose test with the i-STAT Alinity System is substantially equivalent to the predicate device.